High-Dose Ibuprofen in Cystic Fibrosis
AbstractCystic Fibrosis (CF) is the most common lethal genetic disorder in North America and Europe. Most patients succumb to progressive lung disease characterized by an exaggerated neutrophilic inflammation. In animal models of chronic infection, high-dose ibuprofen was demonstrated to reduce inflammation without hindering bacterial clearance. This led to two clinical trials, which demonstrated a benefit in slowing the progression of lung disease in CF. However, concerns about potential adverse effects have limited the use of high-dose ibuprofen in CF patients. There are a variety of potential mechanisms to account for the observed clinical benefit. A better understanding of these mechanisms could potentially lead to more targeted and better-tolerated anti-inflammatory therapies. View Full-Text
Share & Cite This Article
Lands, L.C.; Dauletbaev, N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals 2010, 3, 2213-2224.
Lands LC, Dauletbaev N. High-Dose Ibuprofen in Cystic Fibrosis. Pharmaceuticals. 2010; 3(7):2213-2224.Chicago/Turabian Style
Lands, Larry C.; Dauletbaev, Nurlan. 2010. "High-Dose Ibuprofen in Cystic Fibrosis." Pharmaceuticals 3, no. 7: 2213-2224.